Europe
Vir Biotechnology and GlaxoSmithKline dosed the first patient last week in a Phase II/III clinical trial of VIR-7831, a fully human monoclonal antibody against COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 31, 2020.
As August wraps up, there were still clinical trial announcements, although fewer than earlier this summer. Here’s a look.
AstraZeneca’s Farxiga (dapagliflozin) dramatically prolonged survival in patients with chronic kidney disease in a Phase III clinical trial.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
The trials were identical, multi-center, randomized, vehicle-controlled, double-blind, parallel studies that evaluated tapinarof cream, 1% in adults with plaque psoriasis.
The U.S. Food and Drug Administration (FDA) approved Italy-based Cassiopea SpA’s acne treatment Winlevi. Let’s look at how this new acne treatment was developed.
Biopharma and life sciences companies from around the globe share updates on their business practices and pipelines.
In a regulatory filing with the U.S. Securities and Exchange Commission, Translate Bio indicated that the COVID-19 vaccine it is developing with Sanofi induced an immune response in non-human studies.
The Hadean Platform, a distributed computing platform, streamlines running applications via cloud by removing excessive middleware and helping scale the process – a journey that has taken them from the world of gaming to the modeling a pandemic.
PRESS RELEASES